Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
TLR2	7097	GOLOTIMOD	CHEMBL2103812		DrugBank

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
TLR2	rs11938228	AA + AC	Tumor necrosis factor alpha	efficacy	yes	Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate.	Genotypes AA + AC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	28696418	1449155420
TLR2	rs4696480	TT	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for the UC cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotypes AA + AT.	24776844	1296666743
TLR2	rs1816702	CT + TT	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for the CD cohort. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype CC.	24776844	1296666780
TLR2	rs3804099	CC + CT	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD, CD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.	24776844	1296666774
TLR2	rs4696480	AT + TT	Tumor necrosis factor alpha	efficacy	yes	Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate.	Genotypes AT + TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	28696418	1449155430
TLR2	rs11938228	AA + AC	Tumor necrosis factor alpha	efficacy	yes	Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation.	Genotypes AA + AC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative or Inflammatory Bowel Diseases as compared to genotype CC.	24776844	1296666811
TLR2	rs3804100	CC + CT	morphine	"dosage","efficacy"	yes		Genotypes CC + CT are associated with decreased dose of morphine in women with Pain, Postoperative as compared to genotype TT.	27649267	1450373508